S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
NASDAQ:IMGN

ImmunoGen - IMGN Stock Forecast, Price & News

$3.81
+0.02 (+0.53%)
(As of 03/27/2023 05:42 PM ET)
Add
Compare
Today's Range
$3.74
$3.87
50-Day Range
$3.67
$4.92
52-Week Range
$3.10
$6.63
Volume
1.95 million shs
Average Volume
3.48 million shs
Market Capitalization
$861.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
250.0% Upside
$13.33 Price Target
Short Interest
Bearish
11.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.71mentions of ImmunoGen in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.80) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

409th out of 995 stocks

Pharmaceutical Preparations Industry

188th out of 482 stocks


IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Company News for Dec 30, 2022
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Will ImmunoGen (NASDAQ:IMGN) Spend Its Cash Wisely?
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Company Calendar

Last Earnings
3/01/2023
Today
3/27/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$13.33
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+250.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-222,930,000.00
Net Margins
-204.93%
Pretax Margin
-203.81%

Debt

Sales & Book Value

Annual Sales
$108.78 million
Book Value
$0.71 per share

Miscellaneous

Free Float
218,496,000
Market Cap
$861.24 million
Optionable
Optionable
Beta
0.94

Social Links


Key Executives

  • Mark Joseph EnyedyMark Joseph Enyedy
    President, Chief Executive Officer & Director
  • Renee Lentini
    VP-Finance, Chief Financial & Accounting Officer
  • Anna Berkenblit
    Chief Medical Officer & Senior Vice President
  • Michael J. Vasconcelles
    EVP-Research, Development & Medical Affairs
  • Stacy A. Coen
    Chief Business Officer & Senior Vice President













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

4 analysts have issued 12-month target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 250.0% from the stock's current price.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the start of the year. Since then, IMGN shares have decreased by 23.2% and is now trading at $3.81.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 25,000,000 shares, an increase of 9.6% from the February 28th total of 22,800,000 shares. Based on an average daily trading volume, of 3,470,000 shares, the days-to-cover ratio is presently 7.2 days.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Wednesday, March, 1st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. The biotechnology company had revenue of $41.17 million for the quarter, compared to analyst estimates of $17.18 million. ImmunoGen had a negative trailing twelve-month return on equity of 100.18% and a negative net margin of 204.93%. The firm's revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) earnings per share.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $30.00 million-$35.00 million, compared to the consensus revenue estimate of $117.67 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.90%), Jennison Associates LLC (4.14%), Maverick Capital Ltd. (3.12%), Morgan Stanley (1.93%), Geode Capital Management LLC (1.74%) and Braidwell LP (1.57%).
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $3.81.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $861.24 million and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 3/27/2023 by MarketBeat.com Staff